What is INmune Bio, Inc. (INMB)?

INmune Bio, Inc. (INMB) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of INMB?

The current price of INMB is $1.60. Prices are updated in real time on Stocks360.

What is INMB's price-to-earnings (PE) ratio?

INMB's trailing twelve-month PE ratio is -2.32, based on current price and earnings per share data available on Stocks360.

What is INMB's market capitalization?

INMB's market capitalization is $44,406,062.00, placing it in the small-cap tier.

INmune Bio, Inc. (INMB)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.60

Market Cap

$44.41M

PE (TTM)

-2.32

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.90

Day Range

$1.56 – $1.65

52-wk Range

$1.09 – $2.60

Avg Volume

N/A

Volume

185.89K

INmune Bio, Inc. (INMB) is a publicly traded company in the Healthcare sector. Latest price: $1.60. Market cap $44.41M. Trailing PE -2.32. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $1.73 2026-10-29 · $1.60 (-7.51%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.05 vs est. $-0.21

Beat by $0.16

Next Earnings

Nov 5, 2026

EPS estimate $-0.15

Proprietary Signals

Signal snapshot temporarily unavailable.

About INmune Bio, Inc.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.32×
P/S (TTM)	0.00×
P/B	2.10×
P/FCF (TTM)	-2.72×
EV / EBITDA	-1.50×
EV / Sales	0.00×
Earnings Yield	-43.08%
Free Cash Flow Yield	-36.71%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$27.40M
Net Income (TTM)	-$19.13M
Free Cash Flow (TTM)	-$16.30M
Net Debt	-$17.01M
Working Capital	$17.91M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-82.87%
Return on Invested Capital	-92.78%